**Name of Journal:***World Journal of Meta-Analysis*

**Manuscript NO:** 47201

**Manuscript Type:** SYSTEMATIC REVIEW

**Significance of multivisceral resections in oncologic surgery: A systematic review of the literature**

Nadiradze G *et al*. Significance of MVR in oncologic surgery

Giorgi Nadiradze, Can Yurttas, Alfred Königsrainer, Philipp Horvath

**Giorgi Nadiradze, Can Yurttas, Alfred Königsrainer, Philipp Horvath,** Department of General, Visceral and Transplant Surgery, University of Tübingen, Comprehensive Cancer Center, Tübingen 72076, Germany

**Philipp Horvath,** National Center for Pleura and Peritoneum, Tübingen 72076, Germany

**ORCID number:** Philipp Horvath (0000-0002-2008-3267); Can Yurttas (0000-0001-9720-8243); Alfred Königsrainer (0000-0002-2301-4080); Giorgi Nadiradze (0000-0001-6374-8778).

**Author contributions:** Nadiradze G and Yurttas C contributed equally to this work. Königsrainer A initiated the study and approved the final version of the manuscript; Nadiradze G and Yurttas C participated in developing the manuscript and approved the final version of the manuscript. Horvath P led the literature research, abstracted and analyzed the data and developed the manuscript.

**Conflict-of-interest statement:** We declare that we have no conflict of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared according to the PRISMA 2009 checklist.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Philipp Horvath, MD, Surgeon, Surgical Oncologist,** Department of General, Visceral and Transplant Surgery, University of Tübingen, Comprehensive Cancer Center, Hoppe-Seyler-Strasse 3, Tübingen 72076, Germany. philipp.horvath@med.uni-tuebingen.de

**Telephone:** +49-7071-2986620

**Fax:** +49-7071-295588

**Received:** March 20, 2019

**Peer-review started:** March 20, 2019

**First decision:** May 16, 2019

**Revised:** June 7, 2019

**Accepted:** June 16, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Multivisceral resections (MVR) are often necessary to reach clear resections margins but are associated with relevant morbidity and mortality. Factors associated with favorable oncologic outcomes and elevated morbidity rates are not clearly defined.

***AIM***

To systematically review the literature on oncologic long-term outcomes and morbidity and mortality in cancer surgery a systematic review of the literature was performed.

***METHODS***

PubMed was searched for relevant articles (published from 2000 to 2018). Retrieved abstracts were independently screened for relevance and data were extracted from selected studies by two researchers.

***RESULTS***

Included were 37 studies with 3112 patients receiving MVR for colorectal cancer (1095 for colon cancer, 1357 for rectal cancer, and in 660 patients origin was not specified). The most common resected organs were the small intestine, bladder and reproductive organs. Median postoperative morbidity rate was 37.9% (range: 7% to 76.6%) and median postoperative mortality rate was 1.3% (range: 0% to 10%). The median conversion rate for laparoscopic MVR was 7.9% (range: 4.5% to 33%). The median blood loss was lower after laparoscopic MVR compared to the open approach (60 mL *vs* 638 mL). Lymph-node harvest after laparoscopic MVR was comparable. Report on survival rates was heterogeneous, but the 5-year overall-survival rate ranged from 36.7% to 90%, being worst in recurrent rectal cancer patients with a median 5-year overall survival of 23%. R0 -resection, primary disease setting and no lymph-node or lymphovascular involvement were the strongest predictors for long-term survival. The presence of true malignant adhesions was not exclusively associated with poorer prognosis.

Included were 16 studies with 1.600 patients receiving MVR for gastric cancer. The rate of morbidity ranged from 11.8% to 59.8%, and the main postoperative complications were pancreatic fistulas and pancreatitis, anastomotic leakage, cardiopulmonary events and postoperative bleedings. Total mortality was between 0% and 13.6% with an R0 -resection achieved in 38.4% to 100% of patients. Patients after R0 resection had 5-year overall survival rates of 24.1% to 37.8%.

***CONCLUSION***

MVR provides, in a selected subset of patients, the possibility for good long-term results with acceptable morbidity rates. Unlikelihood of achieving R0 -status, lymphovascular- and lymph -node involvement, recurrent disease setting and the presence of metastatic disease should be regarded as relative contraindications for MVR.

**Key words:** Colorectal cancer; Gastric cancer; Primary; Recurrent; Multivisceral resection; Hyperthermic intraperitoneal chemotherapy; Morbidity

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Multivisceral resections constitute a huge challenge for an interdisciplinary team. Proper patient selection, combined perioperative systemic treatment and en-bloc resection of adherent organs can provide acceptable morbidity-, mortality- and long-term survival rates.

Nadiradze G, Yurttas C, Königsrainer A, Horvath P. Significance of multivisceral resections in oncologic surgery: A systematic review of the literature. *World J Meta-Anal* 2019; In press

**INTRODUCTION**

Patients with locally advanced primary and recurrent cancers constitute a challenge for the interdisciplinary treatment team because the only chance for cure and prolonged survival is complete resection of the tumor with clear margins. Invasion of adjacent organs occurs in 10%-20% of patients suffering from colorectal cancer and gastric cancer. The prerequisite for long- and short-term results is completeness of surgical resection. This aggressive surgical concept is accompanied by pre- and postoperative systemic treatment schedules, consisting of chemotherapy, radiotherapy and chemoradiotherapy. Due to the lack of sufficient and reliable preoperative data the decision in favor of multivisceral resections (MVR) is often made intraoperatively. MVR is defined as the *en-bloc* resection of the tumor and the adjacent organs including reproductive organs and organs of the urinary tract. MVR should therefore always be taken into account if macroscopic complete resection is achievable. Adherence of the primary or recurrent tumor to adjacent structures does not necessarily predict true malignant invasion. Winter *et al*[1] stated that up to two-third of cases are postoperatively classified as inflammatory adhesions rather than true malignant invasion. Furthermore, lysis of adhesions or separation of the adjacent organ from the tumor dramatically increases the risk of recurrence and should be avoided. The significance of palliative MVR for patients with obstruction, fistula and pain is not clearly defined but the data presented in this review suggest that non-curative MVR does not improve patient outcome. Leijssen *et al*[2] showed that patients with a T4 -tumor not undergoing MVR had a poorer outcome regarding overall-, disease-free-, and cancer-specific survival. The indication in favor of MVR for patients with metastatic disease is also common in the current literature but the true benefit of MVR for stage IV disease is unclear.

This review aims to systematically evaluate the current literature on outcomes following MVR for colorectal and gastric cancer and for patients undergoing MVR and HIPEC for peritoneal metastasis of gastrointestinal, especially colorectal, origin.

**MATERIALS AND METHODS**

A systematic review was conducted with reference to the PRISMA statement and the current methodological literature[3,4]. Electronic medical literature databases were screened for appropriate publications from 2000 to 2018. Databases were searched using the following terms: “multivisceral” AND “colon cancer”, “multivisceral” AND “rectal cancer”, “multivisceral” AND “gastric cancer”, “multivisceral AND “cytoreductive surgery”, and “multivisceral” AND “hyperthermic intraperitoneal chemotherapy”. Comments and case reports were excluded. Furthermore, publications that did not report performance of MVR, morbidity and mortality rates, oncologic outcome and publications that included unspecified cancer types were also not included in this systematic review.

For the search terms “multivisceral” AND “colon cancer” and “multivisceral” AND “rectal cancer” 211 records were provided. After the abstracts were screened (level 1 screening) independently by two reviewers 165 publications excluded (Figure 1).

For the search terms “multivisceral” AND “gastric cancer” 93 records were provided. After the abstracts were screened (level 1 screening) independently by two reviewers 71 publications excluded.

After level 2 screening, 37 publications for “Multivisceral resection for colon cancer and rectal cancer”, 16 publications for “Multivisceral resection for gastric cancer and 3 publications for “Multivisceral resections with hyperthermic intraperitoneal chemotherapy” were included.

MVR were defined as resection of more than two organs.

**RESULTS**

MVR for colon cancer and rectal cancer (*n* = 37).

***Study design***

After full-text screening 37 studies were selected that met the inclusion criteria. Of these 37 included studies, 36 were retrospective.

***Demographics***

In total 3112 patients underwent MVR for colon and rectal cancer (1095 for colon cancer, 1357 for rectal cancer and in 660 patient’s origin of primary tumor was not specified (Table 1). Of the 36 studies ten included patients with recurrent colon and rectal cancer. The remainder dealt only with primary colon and rectal cancer. Included studies were published after 1999 to the present time and all but one was retrospective. In total five publications presented patient- and treatment-related data after minimally-invasive MVR. The decision for or against suspected MVR, according to preoperative imaging modalities like CT, MRI, EUS and PET-CT, was made intraoperatively. Every verified adhesion of the primary tumor to adjacent structures was classified as a cT4b -situation. All but seven publications did not report the true pT4b -rate. There were 17 studies that included patient with Stage IV disease. Another seven studies did not specify whether or not patients with metastatic disease were included.

***Pathological features***

In the event of adhesion of adjacent structures to the primary tumor, these adhesions should definitely not be separated intraoperatively. For the surgeon it is not possible to distinguish between inflammatory and malignant adhesions. Hunter *et al*[5] showed that patients with adherent colon cancer and lysis of adhesion, had a local recurrence rate of 69% and a 5-year overall survival rate of only 23%. Of the included studies, 30 publications report the histopathologically confirmed malignant invasion rate. The true pT4b -rate varied from 23% to 77%. Three publications performed multivariate analysis in order to determine whether true malignant invasion into adjacent structures is of predictive value for overall- and progression-free survival[6-8]. Rosander *et al*[7] and Lehnert *et al*[8] did not find malignant invasion to be a predictive factor in multivariate analysis. Rosander *et al*[7] found female sex, adjuvant chemotherapy, low tumor stage and R0-resection to be associated with better overall survival. On the other hand, Lehnert *et al*[8] found intraoperative blood loss, age older than 64 years and UICC stage to be predictive. Contrary to the aforementioned results Chen *et al*[6] found adhesion pattern (inflammatory *vs* malignant) to be highly significantly associated with reduced overall survival for both, colon and rectal cancer patients.

Concerning resection status, 27 studies report R0 rates, ranging from 65% to 100%. In the vast majority of publications R0 *vs* R1 -status was of significant prognostic impact (Table 2). Data show a trend towards decreased R0 -rates in patients undergoing MVR for recurrent cancers, especially rectal cancer. Nielsen *et al*[9], Rottoli *et al*[10] and Vermaas *et al*[11] reported resection status in primary and recurrent rectal cancers and showed decreased R0 -rates for recurrent rectal cancer without being statistically significant (66% *vs* 38%; 71% *vs* 56% and 82% *vs* 58%).

***Morbidity and mortality***

There was heterogeneity in reporting total complication rate, degree of complications and specification of different complications, so that the focus was set on complications, which were reported in the vast majority of publications. The postoperative morbidity rates ranged from 7%[12] to 76.6%[13]. Only one study reported that the occurrence of perioperative complications was an independent predictor of shorter overall survival (HR 3.53)[14].

**Anastomotic insufficiency:** Twelve studies did not report occurrence of anastomotic insufficiency (AI). The remainder reported AI-rates ranging from 0.8%[15] to 19%[16]. There was no structured report on management of AI in the studies included.

**Surgical site infection:** Surgical site infections (SSI) were one of the most common complications ranging from 2.5%[15] to 53%[13]. The differentiation into superficial and deep SSI was inconsistently used in the studies included. Kumamoto *et al*[15] reported the lowest rate of SSI including 118 patients undergoing minimally-invasive MVR. The other studies, looking at minimal-invasive MVR, reported SSI -rates ranging from 12%-17%. The study by Kim *et al*[17] found no statistically significant difference in the occurrence of SSI between the open and the minimally-invasive group.

**Intraabdominal abscess:** Intraabdominal abscess (IAA) formation was not reported in 17 studies. The remainder reported IAA rates ranging from 1%[18] to 21%[19]. Documentation of IAA management was again inconsistently reported in the included studies.

**Re-operation:** The rate of necessary surgical re-intervention was again not reported in 17 studies. In the remaining studies the re-operation rate ranged from 0%[14] to 20%[19].

**Mortality:** In total 15 studies reported mortality rates of 0% and the median mortality rate was 1.3%. The highest reported perioperative mortality rate, namely 10% was reported in the study by Manas *et al*[13].

***Long-term outcomes***

Table 3 shows overall (OS)- and disease-free survival (DFS) rates and depicts factors associated with decreased OS and DFS after MVR for rectal and colon cancers. 5-year OS rate ranged from 36.7%[13] to 90%[20], but the proportion of included patients with metastatic disease differed between those two studies (20% *vs* 0%).

**Local and distant recurrences:** The local control rate expressed by the local recurrence rate were reported in 27 publications and ranged from 1.8% to 66.7%[15]. The aforementioned study and Rosander *et al*[7] showed higher rates of local recurrences after R1 -resection. Distant recurrence rates varied from 10.9%[2] to 45.5%[17]. Patients with metastatic disease, receiving MVR, were also included in the vast majority of publications and the rate of patients with Stage-IV disease varied from 0% to 49%[21].

***Operative approach***

**Laparoscopic *vs* open surgery:** Five publications focused on the perioperative und long-term results of minimally-invasive (laparoscopic and/or robotic) MVR (Table 4). Completeness of surgical resection was not impaired by minimally-invasive MVR and the included studies showed no reduction in lymph -node harvest as compared to open surgery. The conversion rate to open surgery varied from 4.5%[22] to 33%[23]. The most common reasons for conversion were involvement of the small intestine, intraperitoneal adhesions and the need for urologic reconstructive procedures. The minimally-invasive approach offered a reduced length of stay, significantly reduced blood loss but prolonged operative time.

***Chemoradiotherapy***

The number of patients receiving any kind of preoperative therapy, including chemotherapy, radiotherapy and combined chemoradiotherapy, was mentioned in 31 studies. Preoperative chemotherapy was received by 129 (4%) patients, 591 (19%) patients underwent preoperative radiotherapy and 423 (14%) patients were given preoperative combined chemoradiotherapy. Two studies reported on applications of chemoradiotherapy in primary and recurrent colon cancers[20,24]. Cukier *et al*[24] reported that perioperative complication rates were not negatively impacted by chemoradiotherapy. The same results were obtained by Hallet *et al*[20] who stated that the addition of neoadjuvant chemoradiotherapy prior to MVR for recurrent adherent colon cancer did not elevate toxicity-or complication rates.

Six studies reported on patients receiving intraoperative radiotherapy (IORT) [11,22,24-27]. All studies exclusively included patients with primary and or recurrent rectal cancer. Indications for application of IORT were a minimal circumferential free resection margin equal to or less than 2 mm in the study from Vermaas *et al*[11] and the concern for close and/or involved radial margins in the study by Gannon *et al*[28] Only 12 patients in the study by Vermaas *et al*[11] received IORT but no improvement in overall survival was seen.

***Primary vs recurrent rectal cancer***

In total seven publications included primary as well as recurrent rectal cancers[6,9-11,26,28,29]. The studies by Gannon *et al*[28] Nielsen *et al*[9] and Vermaas *et al*[11] included 197 patients and only Gannon *et al*[28] reported that the disease setting was the only significant prognostic factor in favor of primary rectal cancers. This is in line with the results published by Rottoli *et al*[10] who also found the recurrent disease setting to be a negative prognostic factor.

MVR for gastric cancer (*n* = 16).

***Study design***

A total of 93 articles were identified using the aforementioned search algorithm (Figure 1). After full-text screening 16 studies were selected that met the inclusion criteria.

***Demographics***

We identified 16 studies published between 1998 and 2019 describing MVR for a total of 1600 patients with locally advanced gastric cancer (Table 5). One publication reported patient- and treatment-related data after minimally-invasive MVR, whereas the other authors either performed open surgery or did not mention whether an open or laparoscopic approach was chosen[31]. The decision for or against suspected MVR, according to preoperative imaging modalities like CT, MRI, EUS and PET-CT, was made intraoperatively. Every verified adhesion of the primary tumor to adjacent structures was classified as a cT4b -situation. Together with a gastrectomy, mainly surrounding organs like spleen, pancreas or colon were resected. More rarely, the gallbladder or parts of the small bowel or the liver had to be removed.

***Pathological features***

Prior clinically suspected T4-tumor was confirmed in 14%[32]-89.0%[33] of histopathological samples. Involvement of lymph nodes was described in 38.8%[33]-89.3%[34]) of patients.

***Morbidity and mortality***

The rate of morbidity ranged from 11.8%[35] to 59.8%[31] of patients who underwent gastrectomy and MVR (Table 6). Main postoperative complications were pancreatic fistulas and pancreatitis, anastomotic leakage, cardiopulmonary events and postoperative bleedings. Total mortality lay between 0%[35] and 13.6%[33]. R0-resections were achieved in 38.4%[34]-100%[36] of patients.

**Anastomotic insufficiency:** Ten studies did not report the occurrence of anastomotic insufficiency (AI). The remainder reported AI -rates ranging from 0%[37,38] to 19.4%[31]. There was no structured report on management of AI in the studies included.

**Re-operation:** The rate of re-operation was only mentioned in 4 publications and ranged from 0%[37,38] to 13.8%[31].

***Long-term outcomes***

Patients after R0 resection had 5 year overall survival rates of 24.1%[38] to 37.8%[35]. In the multivariate analysis, mostly incomplete resection status[34,39-42] as well as lymph node involvement[31,34,36,39,40,42-45] were found to be negative prognostic factors for survival. Further negative prognostic factors were metastasized stage[35,39], advanced age[44] the number of resected organs[31,42,44,46], no adjuvant chemotherapy[31] and white race[31].

**DISCUSSION**

MVR for locally advanced and adherent colorectal and gastric cancers seems to be a feasible approach that is associated with an acceptable morbidity - and mortality -rate and in a subset of patients good oncologic long-term results can be obtained[15,20,25,42,44,47]. Due to the reduced sensitivity and specificity of preoperative imaging for prediction of true malignant adhesion, the decision in favor of performing MVR is made intraoperatively in the vast majority of cases[1]. It is virtually impossible for the surgeon to differentiate between inflammatory and true malignant adhesions, so that every adherence to the tumor must be considered malignant and the appropriate operative strategy has to be applied. Data on intraoperative lysis of adhesions to the primary tumor, which were proven malignant by histopathological examination, revealed devastating overall survival rates and high local recurrence rates (Hunter *et al*[5]). In this review the true pT4b -rate varied from 23% to 77% and data on the impact of malignant invasion are heterogeneous with two studies[7,8] reporting no impact on overall-survival if malignant adhesions were detected and one study reporting the opposite[6]. It seems it is not the presence of proven malignant infiltration into adherent adjacent organs but the presence other tumor- and treatment-associated factors that are of prognostic importance. This review emphasized the importance of microscopic complete surgical resection, as one of the most predictive factors for overall- and recurrence-free survival[15,48]. These results are further highlighted by the results presented by Nielsen *et al*[9] comparing primary and recurrent rectal cancers. The authors stated that no statistically significant difference in overall survival was seen regarding the disease setting when comparing R0-resections. The remaining studies dealing with primary versus recurrent rectal cancer found the disease setting to be of significant prognostic impact[10,28]. Patient selection for MVR in the recurrent disease setting should be made on a case-by-case basis, because achievement of R0 -resection in these patients can also produce acceptable long-term results. The intraoperative assessment of truly preventing an R1 -resection is virtually not possible, but nevertheless palliative MVR should not be performed as shown by the data from Leijssen *et al*[2]. Authors reported for patients with proven T4 -cancers not undergoing MVR the highest local recurrence rate, namely 21.5% (compared to patients undergoing MVR: 14.5%) and the worst 5-year OS-and DFS rates (46.3% *vs* 52.7% *vs* 70% and 74.1%, respectively).

Apart from the completeness of surgical resection factors like lymph -node and lymphovascular involvement seem to be predictive for survival. López-Cano *et al*[49], Smith *et al*[47] and Harris *et al*[19] showed that lymphatic spread was associated with worse prognosis. Cukier *et al*[24] and Dinaux *et al*[50] discussed the significance of the ypN -stage. Cukier *et al*[24] reported no statistical difference in terms of DFS when comparing ypN0 and ypN1 patients. Contrarily, Dinaux *et al*[50] showed that ypN+ status was significantly associated with overall mortality. Hoffmann *et al*[21] found no difference in terms of OS for pN0 versus pN1 patients after MVR for primary colorectal cancers.

The role of neoadjuvant and adjuvant chemo- (radio-) therapy in short- and long-term results was hardly assessable due to the heterogeneity of data provided. The study by Sanfilippo *et al*[26] showed no significant association between application of neoadjuvant chemotherapy and local pelvic control rate. Dinaux *et al*[50] even found the performance of adjuvant chemotherapy to be significantly associated with overall mortality.

The significance of minimally-invasive MVR was highlighted in a couple of studies (Table 4). The laparoscopic approach for standard -resections for colon - and gastric cancer has already become accepted with low morbidity rates and comparable oncologic long-term results. The acceptance of laparoscopic or robotic MVR is low but the minimally-invasive approach seems to harbor some advantages over the open approach. Table 4 sums up the most important studies, highlighting the fact that minimally-invasive MVR is associated with a reduced operative time, reduced blood loss and transfusion requirement. The conversion rates were low by a comparable lymph-node harvest. Prior to scheduling patients for minimal-invasive MVR, relative contraindications like excessive small bowel- and urologic tract involvement should receive attention.

Our analysis of the so far published results of MVR for patients with locally advanced gastric cancer shows 5-year survival rates of 24.1%-37.8% for patients with an R0-resection, while the rate of morbidity was 11.8% to 59.8% and the rate of mortality 0-15%. The authors of these studies therefore consider MVR for locally advanced gastric cancer to be a potentially beneficial procedure, especially if there is a possibility of curative resection.

Comparable results can also be found for MVR of other abdominal tumor entities such as neuroendocrine tumors or gastrointestinal stroma tumors[51]. Similar approaches were also investigated for locally advanced pancreatic adenocarcinoma and colorectal cancer. With the acceptance of higher rates of morbidity and longer operating times MVR for locally advanced pancreatic adenocarcinoma may lead to a long -term survival comparable to that for standard resections of the pancreas[52].

In conclusion,the main limitation of this review is the mainly retrospective studies included and the heterogeneity in reporting short- and long-term outcomes. Nevertheless, MVR for primary cancers are of significant importance in oncologic surgery providing acceptable morbidity- and mortality rates with good long-term survival for selected patients. Negative selection criteria are incomplete surgical resection, recurrent rectal cancer, and lymph-node and lymphovascular involvement. Stage-IV disease should be regarded as a relative contraindication for MVR.

**Article Highlights**

***Research background***

Multivisceral resections (MVR) still constitute a challenge for the interdisciplinary team. The indications to perform MVR are not clearly defined.

***Research motivation***

Motivation was generated by the fact that there are no recommendations regarding MVR.

***Research objectives***

In order to define indications and factors associated with beneficial oncologic outcomes and reduced perioperative morbidity and mortality this systematic review was conducted.

***Research methods***

We performed a PubMed-search from 2000 to 2018 including articles reporting on MVR in patients with colon-, rectal- and gastric cancer.

***Research results***

Available data shows that MVR from locally advanced colorectal and gastric cancer is a feasible option which is associated with acceptable morbidity- and mortality-rates. Oncologic outcome is favorable when clear resection margins can be obtained.

***Research conclusions***

Patients who are clinically fit and preoperative imaging does not reveal obvious contraindication for radical surgery, the option of MVR should not be abandoned. Clear resection margins are the main goal of aggressive surgical approach.

***Research perspectives***

Perspectives are to evaluate more patient- and treatmenspecific parameters in order to define more clearly patients who are likely to benefit from this approach.

**REFERENCES**

1 **Winter DC**, Walsh R, Lee G, Kiely D, O'Riordain MG, O'Sullivan GC. Local involvement of the urinary bladder in primary colorectal cancer: outcome with en-bloc resection. *Ann Surg Oncol* 2007; **14**: 69-73 [PMID: 17063308 DOI: 10.1245/s10434-006-9031-y]

2 **Leijssen LGJ**, Dinaux AM, Amri R, Kunitake H, Bordeianou LG, Berger DL. The Impact of a Multivisceral Resection and Adjuvant Therapy in Locally Advanced Colon Cancer. *J Gastrointest Surg* 2019; **23**: 357-366 [PMID: 30284199 DOI: 10.1007/s11605-018-3962-z]

3 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

4 **Borowski DW**, Bradburn DM, Mills SJ, Bharathan B, Wilson RG, Ratcliffe AA, Kelly SB; Northern Region Colorectal Cancer Audit Group (NORCCAG). Volume-outcome analysis of colorectal cancer-related outcomes. *Br J Surg* 2010; **97**: 1416-1430 [PMID: 20632311 DOI: 10.1002/bjs.7111]

5 **Hunter JA**, Ryan JA Jr, Schultz P. En bloc resection of colon cancer adherent to other organs. *Am J Surg* 1987; **154**: 67-71 [PMID: 2440334 DOI: 10.1016/0002-9610(87)90292-3]

6 **Chen YG**, Liu YL, Jiang SX, Wang XS. Adhesion pattern and prognosis studies of T4N0M0 colorectal cancer following en bloc multivisceral resection: evaluation of T4 subclassification. *Cell Biochem Biophys* 2011; **59**: 1-6 [PMID: 20740326 DOI: 10.1007/s12013-010-9106-z]

7 **Rosander E**, Nordenvall C, Sjövall A, Hjern F, Holm T. Management and Outcome After Multivisceral Resections in Patients with Locally Advanced Primary Colon Cancer. *Dis Colon Rectum* 2018; **61**: 454-460 [PMID: 29521827 DOI: 10.1097/DCR.0000000000001046]

8 **Lehnert T**, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. *Ann Surg* 2002; **235**: 217-225 [PMID: 11807361 DOI: 10.1097/00000658-200202000-00009]

9 **Nielsen MB**, Rasmussen PC, Lindegaard JC, Laurberg S. A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. *Colorectal Dis* 2012; **14**: 1076-1083 [PMID: 22107085 DOI: 10.1111/j.1463-1318.2011.02893.x]

10 **Rottoli M**, Vallicelli C, Boschi L, Poggioli G. Outcomes of pelvic exenteration for recurrent and primary locally advanced rectal cancer. *Int J Surg* 2017; **48**: 69-73 [PMID: 28987560 DOI: 10.1016/j.ijsu.2017.09.069]

11 **Vermaas M**, Ferenschild FT, Verhoef C, Nuyttens JJ, Marinelli AW, Wiggers T, Kirkels WJ, Eggermont AM, de Wilt JH. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. *Eur J Surg Oncol* 2007; **33**: 452-458 [PMID: 17071043 DOI: 10.1016/j.ejso.2006.09.021]

12 **Takahashi R**, Hasegawa S, Hirai K, Hisamori S, Hida K, Kawada K, Sakai Y. Safety and feasibility of laparoscopic multivisceral resection for surgical T4b colon cancers: Retrospective analyses. *Asian J Endosc Surg* 2017; **10**: 154-161 [PMID: 28124830 DOI: 10.1111/ases.12355]

13 **Mañas MJ**, Espín E, López-Cano M, Vallribera F, Armengol-Carrasco M. Multivisceral Resection for Locally Advanced Rectal Cancer: Prognostic Factors Influencing Outcome. *Scand J Surg* 2015; **104**: 154-160 [PMID: 25260784 DOI: 10.1177/1457496914552341]

14 **Pellino G**, Biondo S, Codina Cazador A, Enríquez-Navascues JM, Espín-Basany E, Roig-Vila JV, García-Granero E; Rectal Cancer Project. Pelvic exenterations for primary rectal cancer: Analysis from a 10-year national prospective database. *World J Gastroenterol* 2018; **24**: 5144-5153 [PMID: 30568391 DOI: 10.3748/wjg.v24.i45.5144]

15 **Kumamoto T**, Toda S, Matoba S, Moriyama J, Hanaoka Y, Tomizawa K, Sawada T, Kuroyanagi H. Short- and Long-Term Outcomes of Laparoscopic Multivisceral Resection for Clinically Suspected T4 Colon Cancer. *World J Surg* 2017; **41**: 2153-2159 [PMID: 28280917 DOI: 10.1007/s00268-017-3976-9]

16 **Li JC**, Chong CC, Ng SS, Yiu RY, Lee JF, Leung KL. En bloc urinary bladder resection for locally advanced colorectal cancer: a 17-year experience. *Int J Colorectal Dis* 2011; **26**: 1169-1176 [PMID: 21526373 DOI: 10.1007/s00384-011-1210-z]

17 **Kim KY**, Hwang DW, Park YK, Lee HS. A single surgeon's experience with 54 consecutive cases of multivisceral resection for locally advanced primary colorectal cancer: can the laparoscopic approach be performed safely? *Surg Endosc* 2012; **26**: 493-500 [PMID: 22011939 DOI: 10.1007/s00464-011-1907-7]

18 **Gezen C**, Kement M, Altuntas YE, Okkabaz N, Seker M, Vural S, Gumus M, Oncel M. Results after multivisceral resections of locally advanced colorectal cancers: an analysis on clinical and pathological t4 tumors. *World J Surg Oncol* 2012; **10**: 39 [PMID: 22336589 DOI: 10.1186/1477-7819-10-39]

19 **Harris DA**, Davies M, Lucas MG, Drew P, Carr ND, Beynon J; Swansea Pelvic Oncology Group. Multivisceral resection for primary locally advanced rectal carcinoma. *Br J Surg* 2011; **98**: 582-588 [PMID: 21656723 DOI: 10.1002/bjs.7373]

20 **Hallet J**, Zih FS, Lemke M, Milot L, Smith AJ, Wong CS. Neo-adjuvant chemoradiotherapy and multivisceral resection to optimize R0 resection of locally recurrent adherent colon cancer. *Eur J Surg Oncol* 2014; **40**: 706-712 [PMID: 24534363 DOI: 10.1016/j.ejso.2014.01.009]

21 **Hoffmann M**, Phillips C, Oevermann E, Killaitis C, Roblick UJ, Hildebrand P, Buerk CG, Wolken H, Kujath P, Schloericke E, Bruch HP. Multivisceral and standard resections in colorectal cancer. *Langenbecks Arch Surg* 2012; **397**: 75-84 [PMID: 21968828 DOI: 10.1007/s00423-011-0854-z]

22 **Shin US**, Nancy You Y, Nguyen AT, Bednarski BK, Messick C, Maru DM, Dean EM, Nguyen ST, Hu CY, Chang GJ. Oncologic Outcomes of Extended Robotic Resection for Rectal Cancer. *Ann Surg Oncol* 2016; **23**: 2249-2257 [PMID: 26856720 DOI: 10.1245/s10434-016-5117-3]

23 **Tei M**, Otsuka M, Suzuki Y, Kishi K, Tanemura M, Akamatsu H. Safety and feasibility of single-port laparoscopic multivisceral resection for locally advanced left colon cancer. *Oncol Lett* 2018; **15**: 10091-10097 [PMID: 29928379 DOI: 10.3892/ol.2018.8582]

24 **Cukier M**, Smith AJ, Milot L, Chu W, Chung H, Fenech D, Herschorn S, Ko Y, Rowsell C, Soliman H, Ung YC, Wong CS. Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience. *Eur J Surg Oncol* 2012; **38**: 677-682 [PMID: 22632848 DOI: 10.1016/j.ejso.2012.05.001]

25 **Crawshaw BP**, Augestad KM, Keller DS, Nobel T, Swendseid B, Champagne BJ, Stein SL, Delaney CP, Reynolds HL. Multivisceral resection for advanced rectal cancer: outcomes and experience at a single institution. *Am J Surg* 2015; **209**: 526-531 [PMID: 25577290 DOI: 10.1016/j.amjsurg.2014.10.014]

26 **Sanfilippo NJ**, Crane CH, Skibber J, Feig B, Abbruzzese JL, Curley S, Vauthey JN, Ellis LM, Hoff P, Wolff RA, Brown TD, Cleary K, Wong A, Phan T, Janjan NA. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. *Int J Radiat Oncol Biol Phys* 2001; **51**: 176-183 [PMID: 11516868 DOI: 10.1016/S0360-3016(01)01610-8]

27 **Vladov N**, Lukanova TS, Trichkov Ts, Takorov I, Mihaylov V, Vasilevski I, Odiseeva E. MULTIVISCERAL RESECTIONS FOR GASTRIC CANCER. *Khirurgiia (Sofiia)* 2015; **81**: 116-122 [PMID: 26887058]

28 **Gannon CJ**, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. *Ann Surg Oncol* 2007; **14**: 1870-1877 [PMID: 17406945 DOI: 10.1245/s10434-007-9385-9]

29 **Fujisawa M**, Nakamura T, Ohno M, Miyazaki J, Arakawa S, Haraguchi T, Yamanaka N, Yao A, Matsumoto O, Kuroda Y, Kamidono S. Surgical management of the urinary tract in patients with locally advanced colorectal cancer. *Urology* 2002; **60**: 983-987 [PMID: 12475654 DOI: 10.1016/S0090-4295(02)01987-8]

30 **Dosokey EMG**, Brady JT, Neupane R, Jabir MA, Stein SL, Reynolds HL, Delaney CP, Steele SR. Do patients requiring a multivisceral resection for rectal cancer have worse oncologic outcomes than patients undergoing only abdominoperineal resection? *Am J Surg* 2017; **214**: 416-420 [PMID: 28622838 DOI: 10.1016/j.amjsurg.2017.05.012]

31 **Tran TB**, Worhunsky DJ, Norton JA, Squires MH 3rd, Jin LX, Spolverato G, Votanopoulos KI, Schmidt C, Weber S, Bloomston M, Cho CS, Levine EA, Fields RC, Pawlik TM, Maithel SK, Poultsides GA. Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. *Ann Surg Oncol* 2015; **22 Suppl 3**: S840-S847 [PMID: 26148757 DOI: 10.1245/s10434-015-4694-x]

32 **Oñate-Ocaña LF**, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincón D, Brom-Valladares R, Herrera-Goepfert R, Ochoa-Carrillo F, Beltrán-Ortega A. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. *J Surg Oncol* 2008; **98**: 336-342 [PMID: 18646043 DOI: 10.1002/jso.21118]

33 **Shchepotin IB**, Chorny VA, Nauta RJ, Shabahang M, Buras RR, Evans SR. Extended surgical resection in T4 gastric cancer. *Am J Surg* 1998; **175**: 123-126 [PMID: 9515528 DOI: 10.1016/S0002-9610(97)00268-7]

34 **Pacelli F**, Cusumano G, Rosa F, Marrelli D, Dicosmo M, Cipollari C, Marchet A, Scaringi S, Rausei S, di Leo A, Roviello F, de Manzoni G, Nitti D, Tonelli F, Doglietto GB; Italian Research Group for Gastric Cancer. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. *JAMA Surg* 2013; **148**: 353-360 [PMID: 23715879 DOI: 10.1001/2013.jamasurg.309]

35 **Kim JH**, Jang YJ, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS. Surgical outcomes and prognostic factors for T4 gastric cancers. *Asian J Surg* 2009; **32**: 198-204 [PMID: 19892622 DOI: 10.1016/S1015-9584(09)60395-X]

36 **Martin RC 2nd**, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. *Ann Surg* 2002; **236**: 159-165 [PMID: 12170020 DOI: 10.1097/00000658-200208000-00003]

37 **Colen KL**, Marcus SG, Newman E, Berman RS, Yee H, Hiotis SP. Multiorgan resection for gastric cancer: intraoperative and computed tomography assessment of locally advanced disease is inaccurate. *J Gastrointest Surg* 2004; **8**: 899-902 [PMID: 15531245 DOI: 10.1016/j.gassur.2004.08.005]

38 **D'Amato A**, Santella S, Cristaldi M, Gentili V, Pronio A, Montesani C. The role of extended total gastrectomy in advanced gastric cancer. *Hepatogastroenterology* 2004; **51**: 609-612 [PMID: 15086216]

39 **Carboni F**, Lepiane P, Santoro R, Lorusso R, Mancini P, Sperduti I, Carlini M, Santoro E. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. *J Surg Oncol* 2005; **90**: 95-100 [PMID: 15844189 DOI: 10.1002/jso.20244]

40 **Molina JC**, Al-Hinai A, Gosseling-Tardif A, Bouchard P, Spicer J, Mulder D, Mueller CL, Ferri LE. Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center. *J Gastrointest Surg* 2019; **23**: 43-50 [PMID: 29663302 DOI: 10.1007/s11605-018-3746-5]

41 **Fujiwara T**, Hizuta A, Iwagaki H, Matsuno T, Hamada M, Tanaka N, Orita K. Appendiceal mucocele with concomitant colonic cancer. Report of two cases. *Dis Colon Rectum* 1996; **39**: 232-236 [PMID: 8620794 DOI: 10.1007/BF02068082]

42 **Mita K**, Ito H, Katsube T, Tsuboi A, Yamazaki N, Asakawa H, Hayashi T, Fujino K. Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer. *J Gastrointest Surg* 2017; **21**: 1993-1999 [PMID: 28940122 DOI: 10.1007/s11605-017-3559-y]

43 **Jeong O**, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. *J Surg Oncol* 2009; **100**: 115-120 [PMID: 19475581 DOI: 10.1002/jso.21306]

44 **Ozer I**, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, Kece C, Atalay F, Akoglu M. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. *Am J Surg* 2009; **198**: 25-30 [PMID: 18823618 DOI: 10.1016/j.amjsurg.2008.06.031]

45 **Isozaki H**, Tanaka N, Tanigawa N, Okajima K. Prognostic factors in patients with advanced gastric cancer with macroscopic invasion to adjacent organs treated with radical surgery. *Gastric Cancer* 2000; **3**: 202-210 [PMID: 11984737 DOI: 10.1007/PL00011718]

46 **Persiani R**, Antonacci V, Biondi A, Rausei S, La Greca A, Zoccali M, Ciccoritti L, D'Ugo D. Determinants of surgical morbidity in gastric cancer treatment. *J Am Coll Surg* 2008; **207**: 13-19 [PMID: 18589356 DOI: 10.1016/j.jamcollsurg.2007.12.050]

47 **Smith JD**, Nash GM, Weiser MR, Temple LK, Guillem JG, Paty PB. Multivisceral resections for rectal cancer. *Br J Surg* 2012; **99**: 1137-1143 [PMID: 22696063 DOI: 10.1002/bjs.8820]

48 **Derici H**, Unalp HR, Kamer E, Bozdag AD, Tansug T, Nazli O, Kara C. Multivisceral resections for locally advanced rectal cancer. *Colorectal Dis* 2008; **10**: 453-459 [PMID: 18070183 DOI: 10.1111/j.1463-1318.2007.01427.x]

49 **López-Cano M**, Mañas MJ, Hermosilla E, Espín E. Multivisceral resection for colon cancer: analysis of prognostic factors. *Dig Surg* 2010; **27**: 238-245 [PMID: 20571272 DOI: 10.1159/000276974]

50 **Dinaux AM**, Leijssen LGJ, Bordeianou LG, Kunitake H, Berger DL. Effects of local multivisceral resection for clinically locally advanced rectal cancer on long-term outcomes. *J Surg Oncol* 2018; **117**: 1323-1329 [PMID: 29205364 DOI: 10.1002/jso.24947]

51 **Hasselgren K**, Sandström P, Gasslander T, Björnsson B. Multivisceral Resection in Patients with Advanced Abdominal Tumors. *Scand J Surg* 2016; **105**: 147-152 [PMID: 26929293 DOI: 10.1177/1457496915622128]

52 **Hartwig W**, Hackert T, Hinz U, Hassenpflug M, Strobel O, Büchler MW, Werner J. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. *Ann Surg* 2009; **250**: 81-87 [PMID: 19561478 DOI: 10.1097/SLA.0b013e3181ad657b]

53 **Park S**, Lee YS. Analysis of the prognostic effectiveness of a multivisceral resection for locally advanced colorectal cancer. *J Korean Soc Coloproctol* 2011; **27**: 21-26 [PMID: 21431093 DOI: 10.3393/jksc.2011.27.1.21]

54 **Ishiguro S**, Akasu T, Fujita S, Yamamoto S, Kusters M, Moriya Y. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. *Surgery* 2009; **145**: 189-195 [PMID: 19167974 DOI: 10.1016/j.surg.2008.09.014]

55 **Bannura GC**, Barrera AE, Cumsille MA, Contreras JP, Melo CL, Soto DC, Mansilla JE. Posterior pelvic exenteration for primary rectal cancer. *Colorectal Dis* 2006; **8**: 309-313 [PMID: 16630235 DOI: 10.1111/j.1463-1318.2005.00938.x]

56 **Laurence G**, Ahuja V, Bell T, Grim R, Ahuja N. Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection. *Am J Surg* 2017; **214**: 432-436 [PMID: 28082009 DOI: 10.1016/j.amjsurg.2016.12.018]

57 **Rizzuto A**, Palaia I, Vescio G, Serra R, Malanga D, Sacco R. Multivisceral resection for occlusive colorectal cancer: Is it justified? *Int J Surg* 2016; **33 Suppl 1**: S142-S147 [PMID: 27398688 DOI: 10.1016/j.ijsu.2016.06.021]

58 **Eveno C**, Lefevre JH, Svrcek M, Bennis M, Chafai N, Tiret E, Parc Y. Oncologic results after multivisceral resection of clinical T4 tumors. *Surgery* 2014; **156**: 669-675 [PMID: 24953279 DOI: 10.1016/j.surg.2014.03.040]

**P-Reviewer:** Kitai C **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** Germany

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Preferred reporting items for systematic reviews and meta-analyses diagram.**

**Table 1 Patient demographics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study/Yr** | ***n*** | **Disease** | **Site** |
| Cukier *et al*[24], 2012  | 33 | Primary | Colon |
| Hallet *et al*[20], 2014  | 15 | Recurrent | Colon |
| Kumamoto *et al*[15], 2017  | 118 | Primary | Colon |
| Leijssen *et al*[2], 2018  | 103 | Primary | Colon |
| López-Cano *et al*[49], 2010 | 113 | Primary | Colon |
| Rosander *et al*[7], 2018 | 121 | Primary | Colon |
| Takahashi *et al*[12], 2017 | 84 | Primary | Colon |
| Tei *et al*[23], 2018 | 29 | Primary | Colon |
| Chen *et al*[6], 2011  | 287; Colon (152); Rectum (135) | Primary Recurrent | Colorectal  |
| Eveno *et al*[58], 2014  | 152; Colon (81); Rectum (71) | Primary | Colorectal |
| Fujisawa *et al*[29], 2002 | 35; Colon (19); Rectum (17) | Primary Recurrent | Colorectal  |
| Hoffmann *et al*[21], 2012  | 78; Colon (52); Rectum (26) | Primary | Colorectal |
| Gezen *et al*[18], 2012  | 90; Colon (43); Rectum (47) | Primary | Colorectal |
| Kim *et al*[17], 2012 | 54; Colon (32); Rectum (22) | Primary | Colorectal |
| Laurence *et al*[56], 2017 | 660; Colon/Rectum not specified | Primary | Colorectal |
| Lehnert *et al*[8], 2002 | 201; Colon (139); Rectum (62) | Primary | Colorectal |
| Li *et al*[16], 2011  | 72; Colon (28); Rectum (44) | Primary | Colorectal |
| Park *et al*[53], 2011 | 54; Colon (23); Rectum (31) | Primary | Colorectal |
| Rizzuto *et al*[57], 2016 | 22; Colon (16); Rectum (6) | Primary | Colorectal |
| Winter *et al*[1], 2007 | 63; Colon (46); Rectum (17) | Primary | Colorectal |
| Bannura *et al*[55], 2006 | 30 | Primary | Rectal |
| Crawshaw *et al*[25], 2015 | 61 | PrimaryRecurrent | Rectal |
| Derici *et al*[48], 2008 | 57 | Primary | Rectal |
| Dinaux *et al*[50], 2018  | 29 | Primary | Rectal |
| Dosokey *et al*[30], 2017 | 34 | Primary | Rectal |
| Gannon *et al*[28], 2007  | 72 | Primary Recurrent | Rectal |
| Harris *et al*[19], 2011 | 42 | Primary | Rectal |
| Ishiguro *et al*[54], 2009 | 93 | Primary | Rectal |
| Mañas *et al*[13], 2014 | 30 | Primary | Rectal |
| Nielsen *et al*[9], 2012 | 90 | Primary Recurrent | Rectal |
| Pellino *et al*[14], 2018  | 82 | Primary | Rectal |
| Rottoli *et al*[10], 2017  | 46 | Primary Recurrent | Rectal |
| Sanfilippo *et al*[51], 2001  | 32 | Primary | Rectal |
| Shin *et al*[22], 2016  | 22 | Primary | Rectal |
| Smith *et al*[47], 2012 | 124 | Primary | Rectal |
| Vermaas *et al*[11], 2007 | 35 | Primary Recurrent | Rectal |

**Table 2 Patient- and treatment- associated parameters after multivisceral resection for colon and rectal cancers**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Resection margin (R0 *vs* R1)** | **Local and distant recurrence** | **Most common resected organs** | **Lymph node involvement** | **Age** | **Blood loss****(mL)** | **Pre-operative (Chemo)-Radiation** | **Complications (AI;SSI;IAA) (Re-OP)** | **Prognostic factors/conclusions** |
| Cukier *et al*[24] | R0: 100% | LR: 6%; DR: 18% | Small bowel (56%); Bladder/ Ureter (54%) | N0: 79% N1: 21% | 64 | NR | RCTX:100% | 6%; 18%; NR (9%) | No statistical difference in terms of disease-free survival when analyzing subgroups stratified by nodal-status ypN0 *vs* ypN1: (*P* = 0.29) |
| Hallet *et al*[20] | R0: 87% | LR: 13%; DR: 13% | Colon (87%) Small bowel (47%) Bladder (40%) | N0: 70% N1: 30% | 60.2 | 1500  | RCTX:100% | NR | Neoadjuvant RCTX for recurrent colon cancer is feasible. No addition of toxicity (radiation plus MVR) |
| Kumamoto *et al*[15] | R0: 95% | LR: R0: 1.8% R1: 66.7%; DR: NR | Small bowel (14%) Bladder (12%) Colorectum (11%) | N0: 62% N1: 28% N2: 10% | 64 | 48 | CTX: 4.4% | (0.8%; 2.5%; 0.8%) (0%) | R1-resection and N+ status predictors of poor prognosisLaparoscopic approach: feasible, low conversion, low R1-rate |
| Leijssen *et al*[2] | R0: 89% | LR: 14.5%; DR: 10.9% | Small intestine (31%); Reproductive organs (9%); Bladder (7%)  | NR | 69 | NR | NR | (1.8%; 3.6%; NR) (2%) | Patients with T4-cancer not undergoing MVR had a significantly poorer outcome regarding overall-, disease-free and cancer-specific survival |
| López-Cano *et al*[49] | R0: 85% | LR: 23%; DR: 19% | Small intestine (42%) Oophorectomy (28%) Bladder (19%) | N0: 35% N1: 32% N2: 34% | 71 | NR | 0% | (NR; 10%; NR) (8%) | Poorly differentiated tumors and stage IV were associated with a poor survival. Significant predictors of disease progression: venous invasion (RR 2.34) and four or more positive lymph nodes (RR 3.99) |
| Rosander *et al*[7] | R0: 93% | LR: R0: 7% R1: 33% DR: 14% | Bowel (45%) Ovaries (24%) Bladder (partial/total): 22%/19% Uterus/Vagina (17%) | N0: 71% N1: 19% N2: 10% | 67 | NR | CTX: 27% RT: 1% RCTX: 5% | (8%; 7%; 7%) (14%) | Female sex, low tumor stage, and adjuvant CTX, and N - but not tumor infiltration per se, were independently associated with better overall survival |
| Takahashi *et al*[12] | R0: 96% | LR: 2% | Bowel (38%); Uterus/Ovaries (5%); Bladder (11%) | NR | 68.5- 71.5 | Lap. completion: 50; Conversion: 366; Lap overall: 57.5; open: 321 | CTX: open: 25% lap: 6% | (4%; NR; NR) (NR) | Overall- and disease-free survival (multivariate) was shorter in the males. Operative approach did not affect overall- and disease-free survival |
| Tei *et al*[23] | R0: 93%-100% | LR: NR; DR: 24% | Small intestine (38%); Bladder (17%); Ovaries (14%) | N0: 48% N1: 24% N2: 28% | 70 | 60-220 | NR | (3%; 17%; 10%) (3%) | S-MVR and M-MVR do not differ significantly in terms of blood loss, operative time and number of harvested lymph nodes. No difference in occurrence of complications. |
| Chen *et al*[6] | NR | NR | Colon cancer: small bowel (40%); Rectal cancer: Bladder (36%)  | NR | NR | NR | NR | NR | Multivariate analysis showed that adhesion pattern was independently associated with overall survival among both colon (*P* = 0.00001) and rectal (*P* = 0.0002) cancer patients |
| Eveno *et al*[58] | R0: 90% | NR | Vagina (25%); Small bowel (23%); Bladder (20%); Ovaries/Uterus (each 19%) | N0: 55% N1: 25% N2: 19% | 63 | NR | RT: 8%; CT: 2%; RCTX: 27% | (3%, 4%; NR) (9%) | Patients with resection of multiple organs had a better survival rate than patients with single organ resection (*P* = 0.0469). |
| Fujisawa *et al*[29] | NR | NR | Bladder (partial/total): 54%/34% | NR | 59 | NR | 0% | NR | Complication rate was higher in pat. undergoing cystectomy *vs* partial cystectomy (58.3% *vs* 10.5%) |
| Hoffmann *et al*[21] | R0: 95% | LR: 2% | 53%: 1 add. Organ27%: 2 add. organs | NR | 69 | NR | RCTX (rectal): 35% | (9%; 9%; NR) (19%) | No significant differences in overall survial: colon vs. rectal cancer (*P* = 0839); lap *vs* open (*P* = 0.610); emergency *vs* planned (*P* = 0.674), pN0 *vs* pN1 (*P* = 0.658) |
| Gezen *et al*[18] | R0: 91% | NR | Ovaries: 27%; Bladder: 26%; Small bowel: 21%; Uterus: 19% | NR | 59 | 450 (non-MVR: 250) | NR | (2%; 3%; 1%) (2%) | MVR do not alter the rates of sphincter-saving procedures, morbidity and 30-d mortality. |
| Kim *et al*[17] | R0: 71% | LR: 7.7% (lap) and 27.3% (open) *P* = 0.144) DR: 15.4% (lap) *vs* 45.5% (open) *P* = 0.091) | Small bowel: 10%; Bladder: 10%; Seminal vesicle: 13%; Prostate: 6% | NR | 68 | lap: 269; open: 638 | RCTX: 50% of rectal cancer patients | (12%; 8%; NR) (NR) | No adverse long-term oncologic outcomes of laparoscopic MVR were observed |
| Laurence *et al*[56] | NR | NR | NR | NR | 64 | NR | RT: 62% | NR | Female gender, tumor grade 2, MVR were significant protective factors of mortality |
| Lehnert *et al*[8] | R0: 65% R1: 9% R2: 26% | LR: 7% DR: 13% Both: 4% | Small bowel: 29%; Bladder: 24%; Uterus: 13% | NR | 64 | < 1000 mL: 37%; 1000-2000 mL: 13%; > 2000 mL: 10% | RT/CT/RCTX: 40% of R0 resected patients | (5%; 9%; 1%) | Intraoperative blood loss, age older than 64 and UICC stage but not histologic tumor infiltration *vs* inflammation were prognostic factors |
| Li *et al*[16] | NR | LR at 5 years: 15% DR: 14% | Bladder (partial/total): 56%/19% | NR | 67 | Partial cystectomy: 0; Urologic reconstruction: 1700 | 0% | (19%; 25; 6%) (4%) | Negative prognostic factors: age older than 70 years; receiving palliative resection and not involvement of the bladder dome |
| Park *et al*[53] | NR | NR | Small bowel: 24%; Ovary: 17%; Bladder 14% | NR | 64 | NR | NR | (6%; 11%; 9%) (NR) | MVR was associated with a two times higher complications rate compared to standard resections. |
| Rizzuto *et al*[57] | R0: 91% | NR | Small bowel: 36%; Bladder: 27%; Vagina/Uterus/Ovaries: each 22% | N0: 50% N+: 50% | 62 | NR | RCTX: 28% | (11%; 14%; 5%) (NR) | Patients with rectal cancer and occlusive disease had worse prognosis |
| Winter *et al*[1] | R0: 89% | LR: 14% | Bladder (partial): 84% | N0: 65% N1: 35% | 63 | NR | RCTX: 37% | (3%; NR; NR) (NR) | Bladder reconstruction is achievable in most patients. Margin- and node-negative patients benefit the most. |
| Banamura *et al*[56] | NR | LR: 13%; DR. 23%: Both: 20% | APR: 30%; PPE: 70% | NR | 57 | NR | RCTX: 20% | (3%; 27%; NR) (NR) | PPE showed prolonged operative time, higher postoperative complications, a trend towards a poor prognosis in recurrence and survival. |
| Crawshaw *et al*[25] | R0: 87% | LR: 16% | Bladder: 49%; Vagina: 38%; Prostate: 31%; Uterus: 31%; Ovaries: 20%; Small bowel: 10% | NR | 62 | 800 | RCTX: 90% | (NR; 7%; 12%) (NR) | Sphincter perseveration did not affect oncologic outcomes. |
| Derici *et al*[48] | R0: 75% | LR: 18% | Adnexa: 47%; Uterus: 32%; Bladder: 30% | NR | 60 | NR | RCTX: 51% | (7%; 19%; NR) (NR) | Lymph node status pN0 (*P* = 0.007) and R0 resection (*P* = 0.005) were independently significant factors in the multivariate analysis for overall survival. |
| Dinaux *et al*[50] | R0: 100% | LR. 3%; DR: 21%  | Bladder: 28%; Prostate: 21%; Ovaries: 20%; Uterus: 20% | NR | 55 | NR | CTX. 100%; RCTX: 97% | (3%; 14%; 3%) (NR) | Chance of overall mortality significantly increased for patients. who underwent MVR, for administration of adjuvant CTX, for Pn+ and ypN+ status |
| Dosokey *et al*[30] | NR | LR. 3% DR: 11% | Vagina: 50%; Prostate: 30%; Bladder: 33% | NR | 66 | 549 | CTX: 97% RT: 92% | (16%; NR; NR) (NR) | Patients with APR only had a longer 5 yr overall survival and a longer disease-free survival compared to patients undergoing MVR |
| Gannon *et al*[28] | R0: 90% | Primary: LR: 9%, LR+DR: 13%, DR:22%; Recurrent: LR: 4%, LR+DR: 48%, DR:15% | TPE: 47% SLE: 47% PPE: 33% | NR | 52 | NR | RCTX: 85% | (NR; 4%; 11%) (4%) | A significant difference in 5-yr disease-free survival was found between primary and recurrent tumors (52% *vs* 13%, *P* < 0.01). |
| Harris *et al*[19] | R0: 93% | LR: 7% | Bladder+ Prostate: 55%Uterus: 24% | N0: 52% N1: 29% N2: 17% N3: 2% | 62 | NR | RCTX: 74% | (5%; 5%; 21%) (20%) | Association with worse overall survival in multivariate analysis: metastatic disease, pT4N1 stage, vascular invasion. |
| Ishiguro *et al*[54] | R0: 98% | LR: 9% DR: 25% | Uterus+ Bladder+ Rectum: 89% | N0: 57% N+: 43% | 55 | NR | RCTX: 14% | (4%; 23%; 8%) (9%) | Patients with positive lateral pelvic lymph node had a higher probability to recur and a decreased 5-yr over all survival. |
| Mañas *et al*[13] | R0: 73% | LR: 37% DR: 35% | Uterus/Ovaries (each): 53%; Vagina. 27%; Seminal vesicle: 23% | N0: 40% N1: 27% N2: 34% | 68 | NR | RCTX: 20% | (13%; 53%; 10%) (NR) | Multivariate analysis showed that nodal involvement was independent predictor of poor survival (> 4 pos. nodes RR: 9.06 (*P* = 0.006) |
| Nielsen *et al*[9] | Primary:R0: 66% Recurrent: R0: 38%  | NR | TPE with sacrectomy: 22% | NR | 63 | NR | RT: 65% | (4%; 20%; 7%) (NR) | There was no statistically significant difference in overall survival between primary and recurrent disease when comparing R0 resections. |
| Pellino *et al*[14] | R0: 77% | LR: 16% DR: 22% | Not clearly specified  | N0: 13% N1: 29% N2: 43% | 62 | NR | RT: 54% | (NR; 37%; 10%) (10%) | Perioperative complications were independent predictors of shorter survival (HR 3.53) |
| Rottoli *et al*[10] | Primary:R0 71%, Recurrent: R0: 56% | Primary: LR: 18% DR: 29% Both: 7%; Recurrent: LR: 22% DR: 33% Both: 17% | Sacrectomy: Primary: 18% Recurrent: 22%) | N0: 41% N1: 15% N2: 37% | 57 | Primary: 600 Recurrent: 750 | 65% (not specified) | NR | The long-term disease-free survival of patients undergoing pelvic exenteration is significantly worse when the procedure is performed for recurrent rectal cancer, regardless of the tumor involvement of the resection margins. |
| Sanfilippo *et al*[51] | NR | LR: 20% DR: 44% | Vagina: 66%; Bladder/Prostate: 14%; Bladder/Vagina: 6%; Vagina/Uterus/Ovaries: 6% | N0: 72% N1: 9% N2: 9% | 55 | NR | RCTX: 100% | (NR; 19%; 6%) (9%) | No significant association with pelvic control rate and age, sex, cN-stage, tumor distance from the anal verge, clinical tumor length, tumor circumference, tumor mobility, obstruction, grade, neoadjuvant CTX, and MVR |
| Shin *et al*[22] | R0: 100% | LR: 4%  | Prostate: 36%; Vagina: 23%; Small bowel: 14%; Bladder wall: 14% | N0: 41% N1: 46% N2: 14% | 54 | 225 | RCTX: 82% | (NR; 17%; 17%) (13%) | Robotic MVR including resection of lateral pelvic lymph nodes is feasible with acceptable morbidity and no conversion. |
| Smith *et al*[47] | R0: 85% | LR. 19%  | Vagina: 52%; Uterus: 23%; Bladder: 11% | N0: 60%N+: 40% | 63 | NR | RCTX: 73% RT: 2%  | (6%; 19%; 6%) (at least 1%) | 5-yr overall survival in stage I-III: Tumor category (T3-4 *vs* T0-2: HR 2.80), Node category (N1-2 *vs* N0: HR 1.75), Involved resection margin: HR = 2.19), lymphovascular invasion (L0 *vs* L1: HR 1.56) |
| Vermaas *et al*[11] | Primary:R0: 82%; Recurrent: R0: 58% | LR at 5-yr: Primary: 12%; Recurrent: 40% | TPE: 83%TPE an sacral bone: 11%; TPE with coccygeal bone: 6% | N0: 37% N1: 6% N2: 6%  | 58 | NR | RT: 97% | (NR; 26%; NR) (9%) | Patients with recurrent rectal cancers have a higher rate of complications, a high distant metastasis rate and a poor overall survival  |

 CTX: Chemotherapy; MVR: Multivisceral resection; S-MVR: Single-port MVR; M-MVR: Multi-port MVR; HR: Hazard ratio; RR: Relative risk; APR: Abdominoperioneal resection; PPE: Posterior pelvic exenteration; RCTX: Chemoradiotherapy; TPE: Total pelvic exenteration; LR: Local recurrence; DR: Distant recurrence; AI: Anastomotic insufficiency; SSI: Surgical site infections; IAA: Intraabdominal abscess; RT: Radiotherapy; NR: Not reported.

**Table 3 Morbidity, mortality and survival rates after multivisceral resection for colon and rectal cancer**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study**  | **Follow-up (mo)**  | **Morbidity (%)** | **Mortality (%)** | **Survival1** | **Stage IV disease (%)** | **True pT4b (%)** |
| Cukier *et al*[24] | 36 | 36 | 0 | 3-yr OS: 85.9%; 3-yr DFS: 73.7% | 0 | 67 |
| Hallet *et al*[20] | 54 | 33.3 | 0 | 90%; 5-yr DFS: 63.5% | 0 | 50 |
| Kumamoto *et al*[15] | 32 | 17.8 | 0.8 | 87% | 12 | 45 |
| Leijssen *et al*[2] | 48.5 | 25 | 0 | 5-yr OS (pT3): 63%; 5-yr OS (pT4): 70% | 0 | 24 |
| López-Cano *et al*[49] | 74.9 | 47.8 | 7.1 | 48%; 5-yr DFS: 46.3 mo | 20 | 65 |
| Rosander *et al*[7] | 28 | 37% (≥ Grade III) | 5 | 60.8% for the infiltration group; 86.9% for the inflammation group | 0 | 63 |
| Takahashi *et al*[12] | 48.4 | LAP: 7OPEN: 36 | 0 | 3-ys OS (open): 79.8%; (lap): 92.8% | 25 | 50 |
| Tei *et al*[23] | 34 | 37.9 | 0 | 3-yr OS Stage II-III (S-MVR/M-MVR): 81.8%/80.0%3-yr DFS Stage II-III (S-MVR/M-MVR: 58.3%/70.0% | 28 | 34 |
| Chen *et al*[6] | NR | 11.5 | NR | 59% (Colon/inflammation)39% (Colon/invasion)63% (Rectum/inflammation); 42% (Rectum/invasion) | 54 | 55 |
| Eveno *et al*[58] | 48 | 12 | 1.3 | 77%; 3-yr OS (without stage IV disease): 89%; 5-ys DFS: 58% | 13 | 65 |
| Fujisawa *et al*[29] | 42 (mean) | NR | NR | 3-yr OS (colon/bladder sparing): 90%; (colon/nonsparing): 67%; 3 yr OS (rectal/bladder sparing): 50%; (rectal/nonsparing): 67% | NR | NR |
| Hoffmann *et al*[21] | NR | 34.6 | 7.7 | 55% (if curative) | 49 | 63 |
| Gezen *et al*[18] | 25 (mean) | 24.4 | 4.4 | 69.4% | 12 | 34 |
| Kim *et al*[17] | 35/40 (mean) | LAP: 21OPEN: 44 | 0 | LAP: 60.5%; OPEN 48% | 33 | 44 |
| Laurence *et al*[56] | NR | NR | NR | 52.7% | 3 | NR |
| Lehnert *et al*[8] | 71 | 33 | 7.5 | 51% | 5 | 50 |
| Li *et al*[16] | 64.3 | 61 | 5.6 | 50%; 59%: if curative | 21 | 47 |
| Park *et al*[53] | NR | 35.2 | 3.1 | 58% | 0 | 44 |
| Rizzuto *et al*[57] | NR | 55 | 0 | 3-yr OS (non-occlusive): 58.4%; (occlusive): 33.3% | 0 | 77 |
| Winter *et al*[1] | 84 | 18 | 1.5 | 57%; 61% (R0); 17% (R1)77% (R0, N0); 28% (R0, N+) | NR | 54 |
| Banmura *et al*[56] | 32 | 50 | 0 | Local recurrence rate: 30% | 33 | 63 |
| Crawshaw *et al*[25] | 27.8 | 57.4 | 0 | 49.2%; 5-yr DFS: 45.3% | 0 | 39 |
| Derici *et al*[48] | 40.4 (mean) | 38.6 | 3.5 | 49%; 3-yr OS: 81.6% | 0 | 58 |
| Dinaux *et al*[50] | 38.2 | 72.4 | 0 | OS: 45 mo | 0 | 24 |
| Dosokey *et al*[30] | 32(mean) | 39 | 0 | 67%; 5-ys DFS: 79% | 0 | NR |
| Gannon *et al*[28] | 40 | 43 | 0 | 48%; Primary: 65% Recurrent: 22%; 5-yr DFS. 38%; Primary: 52% Recurrent: 13% | NR | NR |
| Harris *et al*[19] | 30 | 50 | 0 | 5-yr OS (R0): 48%; R1/R2: 33% | 14 | 52 |
| Ishiguro *et al*[54] | 40 | 39.8 | 2.2 | 52%; 5-yr DFS: 46% | NR | 49 |
| Mañas *et al*[13] | 28.8 | 76.6 | 10 | 36.7% | 20 | 67 |
| Nielsen *et al*[9] | 12 | 51 | 2.2 | 5-yr OS (prim.): 46%; (rec.):17% | 0 | NR |
| Pellino *et al*[14] | NR | 54.9 | 2.4 | 67% | NR | 70 |
| Rottoli *et al*[10] | 32.5/56.6 | 33Primary: 32%Recurrent: 33% | 4 | 5-ys DFS (primary): 46%(recurrent): 24% | NR | NR |
| Sanfilippo *et al*[51] | NR | 25 | NR | 4-yr OS: 69% | 0 | 44 |
| Shin *et al*[22] | 30 | 41.7 | 0 | 80% | 27 | 23 |
| Smith *et al*[47] | NR | 47.6 | 0.8 | 53.3%; M0: 59% | 20 | 44 |
| Vermaas *et al*[11] | 28 (mean) | 69; Primary: 61; Recurrent: 83 | 3 | 52% (primary); 3-yr OS (recurrent): 32% | NR | 43 |

 1 if not specified 5-yr OS is reported. S-MVR: Single-port laparoscopic multivisceral resection; M-MVR: Multi-port laparoscopic multivisceral resection; NR: Not reported.

**Table 4 Patient- and treatment- associated parameters of minimal-invasive multivisceral resection for colon and rectal cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study**  | **Resection margin (R0 *vs* R1)** | **Lymph-node harvest (*n*)** | **Conversion rate** | **Reason for conversion** | **Blood loss (mL)** | **Operative time (min)** | **LOS (d)** |
| Kumamoto *et al*[15] | R0: 95% | 26 | 6.8% | Excessive tumor fixation (*n* = 4); Suspicion of invasion to the duodenum (*n* = 2); Intraperitoneal adhesion (*n* = 2) | 49 | 254 | 11 |
| Takahashi *et al*[12] | R0: 96% | 34Open: 33 | 12% | The conversion rate was highest in cases involving the urinary tract (40%) | 50; Open: 321 | 279; Open: 255 | 14; Open: 22.5 |
| Tei *et al*[23] | R0: S-MVR: 100%; M-MVR: 93% | S-MVR: 30; M-MVR: 25 | S-MVR 🡪 M-MVR: 14%; M-MVR 🡪 Open: 33% | Small intestine involvement  | S-MVR: 60; M-MVR: 220 | S-MVR: 222; M-MVR: 255 | S-MVR: 11; M-MVR: 18 |
| Kim *et al*[17] | R0: 71% | 34; Open: 40 | 7.9% | NR | 268; Open: 637 | 330; Open: 257 | 21.9; Open: 21 |
| Shin *et al*[22] | R0: 100% | 20 | 4.5% | Unable to tolerate Trendelenburg position and intraperitoneal adhesions | 225 | 421 | 4.5 |

 LOS: Length of hospital stay; S-MVR: Single-port multivisceral resection; M-MVR: Multi-port MVR.

**Table 5 Patient- and treatment- associated parameters after multivisceral resection for gastric cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Resection margin (R0 *vs* R1)** | **Most common resected organs** | **Lymph node involvement** | **Age** | **Blood transfusion** | **Complications (AI) (Re-OP)** | **Other prognostic factors** |
| Carboni *et al*[39], 2005 | R0 61.5%; R1 27.7%; R2 10.8% | Spleen: 48%; Pancreas: 43%; Colon: 25% | 86.2% | 61 | NR | (1.5%) (1.5%) | Lymph-node involvement and metastatic disease |
| Colen *et al*[37], 2004 | NR | Spleen: 62%; Pancreas 57%; Colon: 24% | NR | 67.5 | NR | 0% (NR) | NR |
| D'Amato *et al*[38], 2004 | R0: 69% | Pancreas: 62%; Colon: 12% | NR | NR | NR | (0%) (NR) | NR |
| Jeong *et al*[43], 2009 | R0: 78.3%; R+: 21.7% | Spleen: 47%; Pancreas: 61%; Colon: 24% | N+: 90.1% | 59 | NR | (6.7%) (11%) | Lymph-node and lymphovascular involvement |
| Kim *et al*[35], 2009 | R0: 43%; R1: 15%; R2: 74% | Spleen: 38%; Pancreas: 29%; Colon: 56% | NR | NR | NR | (2.9%) (0%) | histologic type, M stage, peritoneal metastasis, curability and treatment groups |
| Martin *et al*[36], 2002 | R0: 100% | Spleen: 67%; Pancreas: 19%; Colon: 6%; Liver: 4%Gallbladder: 7% | N0: 35%N+: 65% | 66 | NR | (NR) (NR) | Lymph-node involvement and > pT3 |
| Oñate-Ocaña *et al*[32], 2008 | R0: 58.1%; R1: 18.9%; R2: 23% | Spleen: 68%; Pancreas: 26%; Colon: 12%; Liver: 9% | NR | NR | NR | (NR) (NR) | NR |
| Ozer *et al*[44], 2009 | NR | Pancreas: 54%; Colon: 32%; Liver: 18% | NR | 58 | NR | (8.9%) (NR) | Advanced age, lymph node involvement, and resection of more than 1 additional organ were significant prognostic factors for survival. |
| Persiani *et al*[46], 2008 | R0: 320; R1: 39; R2: 29% | Spleen: 84%; Pancreas: 25%; Colon: 10% | NR | 63.4 | NR | (NR) (NR) | Splenectomy, D2 lymphadenectomy, and age greater than 64 yr were the only factors predictive of overall morbidity. |
| Shchepotin *et al*[33], 1998 | NR | Spleen: 43%; Pancreas: 69%; Colon: 45%Liver: 29% | N+: 38.8% | NR | NR | (3.7%) (NR) | NR |
| Isozaki *et al*[45], 2000 | NR | Pancreas + Spleen: 36%; Pancreatoduodenectomy: 7% | N0 = 13%; N1 = 36%; N2 = 25%; N3 = 12% | NR | NR | (NR) (NR) | Location of the tumor, lymph node metastasis, histological depth of invasion, and extent of lymph node dissection |
| Molina *et al*[40], 2019 | R0: 94% | Pancreas (49%); Spleen (34%) Liver (29%). | N+: 80% | 64,5 | NR | (NR) (NR) | Lymph-node involvement and R1-status. |
| Mita *et al*[42], 2017 | R0: 82.5%; R1: 17.5% | Spleen 29.1%; Pancreas: 46.6%; Colon: 13.6%; Liver: 11.7% | N+: 84.5% | 70 | NR | (NR) (NR) | Resection status |
| Vladov *et al*[38], 2015 | R0: 75% | Spleen: 76.7%; Pancreas:40%; Colon: 18.3%; Liver 15% | NR | NR | NR | (NR) (NR) | NR |
| Tran *et al*[31], 2015 | R1: 15.5 | Spleen: 48%; Pancreas:27% Liver 14%Colon: 13% | N0: 34.5% | 64 | NR | (11.5%) (13.8%) | MVR with pancreatectomy, was significantly associated with decreased survival, along with T-stage, N stage, perineural invasion, and  |
| Pacelli *et al*[34], 2013 | R0: 38.4% | Pancreas 46; Colon 43 | N+: 89.3% | NR | NR | (7%) (NR) | Lymph-node involvement and incomplete resection |

MVR: Multivisceral resection; NR: Not reported; AI: Anastomotic insufficiency.

**Table 6 Morbidity, mortality and survival rates after multivisceral resection for gastric cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study**  | ***n*** | **Follow-up (mo)**  | **Morbidity (%)** | **Mortality (%)** | **Survival** | **Stage IV (%)** | **True pT4b (%)** |
| Carboni *et al*[39], 2005 | 65 | 13 | 27.7 | 12.3  | OS: 21.8 mo | 46 | 80 |
| Colen *et al*[37], 2004 | 21 | NR | 39 | 10  | OS: 30 mo | NR | 38 |
| D'Amato *et al*[38], 2004 | 52 | NR | 34.6 | 1.9 | OS: 31 mo | NR | NR |
| Jeong *et al*[43], 2009 | 71 | 17.6  | 26.8 | NR | 3-yr OS: 36.4% | 76 | 63 |
| Kim *et al*[35], 2009 | 34 | NR | 11.8 | 0 | OS: 37.8 mo | 38 | NR |
| Martin *et al*[36], 2002 | 268 | NR | 39.2 | NR | OS: 63 mo | NR | 21 |
| Oñate-Ocaña *et al*[32], 2008 | 74 | NR | 26.9 | NR | OS: 30.5 mo | NR | 14-38 |
| Ozer *et al*[44], 2009 | 56 | 10.8  | 37.5 | 12.5 | 3-yr OS: 53.3% | 62 | 66 |
| Persiani *et al*[46], 2008 | 51 | NR | 16.2 | 2.3  | NR | 79 | 19.6 |
| Shchepotin *et al*[33], 1998 | 353 | NR | 31.2 | 13.6 | 5-yr OS: 25% | NR | 89.0 |
| Isozaki *et al*[45], 2000 | 86 | NR | NR | NR | 5-yr OS: 35% | NR | 53 |
| Molina *et al*[40], 2019 | 35 | 31  | 46 | 3 | 5-yr OS. 34% | NR | 40 |
| Mita *et al*[42], 2017 | 103 | 23.0  | 37.9 | 1.0 | 3-yr OS: 42.1% | 0 | 57 |
| Vladov *et al*[38], 2015 | 60 | NR | 28.3  | 6.7  | 5-yr OS: 24.1% | NR | 70 |
| Tran *et al*[31], 2015 | 159 | NR | 59.8  | 4.3  | 5-yr OS:MVR with pancreatectomy: 20%; MVR without: 36% | 0 | 67 |
| Pacelli *et al*[34], 2013 | 112 | 18.7  | 33.9  | 3,6 | 5-yr OS: 27.2% | NR | 88 |

OS: Overall survival; NR: Not reported; MVR: Multivisceral resection.